Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer
880.6500 -11.85 (-1.33%)
NSE May 06, 2025 15:31 PM
Volume: 1.0M
 

880.65
-1.33%
Prabhudas Lilladhar
trial of the vaccine on 28,000 volunteers, including 1400 subjects in the age group of 12-17 age group. With favorable and acceptable safety profile, the approval was unique as it allows ZyCoV-D to be administered (first time in India) with adolescent age group (12-17 yrs) along with adult population (18 yrs and above). CDH also applied for 2-dose vaccine which may take another 1-2 months for expert group of DCGI to evaluate its efficacy profile data. Thermo-stability (2-8degree temp. for storage) of the vaccine helps in easing storage and transportation costs. Stock filling of the vaccine and commercial...
Zydus Lifesciences L.. has an average target of 1052.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended